MAM
Publicis’s Nakul Chopra is chairman of Goafest 2016 Organizing Committee
MUMBAI The Advertising Club and Advertising Agencies Association of India have announced Goafest 2016 with Publicis South Asia, CEO Nakul Chopra as the chairman of Goafest Organizing Committee.
Commenting on his appointment, Advertising Agencies Association of India (AAA’s of I) president Ambi M G Parameshwaran said “Nakul has been in this industry for over 30 years now. He has been leading Publicis in India through this last decade. I am very excited to see what plans he has in store for us this year.”
The Advertising Club president Raj Nayak too welcomed the appointment saying, “This is wonderful news. Nakul has been instrumental in driving Goafest to success in the recent past. With his proven track record in managing high performing agencies, he is truly the best man for the job! I look forward to work with him to make Goafest 2016 a roaring success.”
To have been given the opportunity to Chair the Goafest Organizing Committee is an honor. There’s still a lot of work to do in strengthening Goafest and together, I hope we can build upon the good work of the past years,” added Chopra on his new role.
The other members on the committee are:
President, Advertising Agencies Association of India (AAA’s of I) & Advisor, FCB Ulka Advertising | Ambi M G Parameshwaran
Founder, Chairman and MD at Madison World | Sam Balsara
Chief Executive Officer at Contract Advertising | Rana Barua
Chairman and CEO at Dentsu Aegis Network | Ashish Bhasin
Managing Director at Jaya Advertising | Jaideep Gandhi
CEO at Group M, South Asia | CVL Srinivas
CEO at LHAMPL | Shashi Sinha
CEO at JWT | Tarun Rai
Group CEO at Madison Media | Vikram Sakhuja
Group CEO at Zee Media Corporation | Bhaskar Das
Chief Corporate Sales and Marketing Officer at Dainik Bhaskar Group | Pradeep Dwivedi
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
